Healthcare
Scopus BioPharma Inc.(SCPS)
Live Price
Offline$0.0004
+0.00% today
1Y Change
-96.00%
Window
Jun 20, 2025 → Jun 16, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- +65.8%
- Dividend Yield
- 0.0%
Coverage: 251 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scopus BioPharma Inc. (SCPS) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 96.0% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +65.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +65.8%, free cash flow +28.9% with operating margin 0.0% and ROIC 164.4%. Stock Foundry combines SCPS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +65.8%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCPS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCPS Max Drawdown
-97.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SCPS and SPY.
Company Overview
Scopus BioPharma Inc.
Other OTC
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
- Leadership
- Alan D. Horsager
- IPO Date
- Dec 16, 2020
- Employees
- 13
- Street Address
- 420 Lexington Avenue
- Mailing
- New York City, NY, 10170
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 479 2513
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 0.0
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- +65.8%
- Free Cash Flow
- +28.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 911.7%
- ROIC
- 164.4%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.05
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.